SES AUA 2025: Overall Survival with Darolutamide Versus Placebo in Combination with Androgen Deprivation Therapy and Docetaxel Accounting for Subsequent Therapy: A Sensitivity Analysis from ARASENS
SES AUA 2025, prostate cancer, metastatic hormone sensitive prostate cancer (mHSPC), ARASENS trial, Darolutamide, Androgen Deprivation Therapy (ADT), abiraterone, enzalutamide, cabazitaxel.